MAPK3 and Parkinson disease: There are two novel aspects of our study: (1) P2Y6R can be used as a potential clinical biomarker of PD and (2) microglial P2Y6R is involved in the neuroinflammation through an autocrine loop based on LPS-triggered UDP secretion and accelerated neuroinflammatory responses through the ERK1/2 pathway.